bosutinib (Rx)

Brand and Other Names:Bosulif
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 100mg
  • 400mg
  • 500mg
more...

Chronic Myelogenous Leukemia

Newly-diagnosed chronic phase Philadelphia chromosome positive

  • Indicated for newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML)
  • 400 mg PO qDay with food

Chronic, accelerated, or blast phase Philadelphia chromosome positive

  • Indicated for chronic, accelerated, or blast phase Ph+ CML in patients resistant to or intolerant to other therapies, including imatinib
  • 500 mg PO qDay with food

Dose escalation

  • Dose escalation allowed in patients with Ph+ CML who did not achieve or maintain a hematologic, cytogenetic, or molecular response and did not have ≥Grade 3 adverse reactions at the recommended starting dose
  • May increase dose by 100-mg increments once daily; not to exceed 600 mg/day

Dosage Modifications

Renal impairment

  • Hemodialysis: Safety and efficacy not established
  • For patients who have declining renal function while on bosutinib who cannot tolerate the starting dose, follow dose adjustment recommendations for toxicity
  • Newly diagnosed chronic phase Ph+ CML
    • CrCl 30-50 mL/min: 300 mg PO qDay
    • CrCl <30 mL/min: 200 mg PO qDay
  • Chronic, accelerated, or blast phase Ph+ CML
    • CrCl 30-50 mL/min: 400 mg PO qDay
    • CrCl <30 mL/min: 300 mg PO qDay

Hepatic impairment

  • Mild to severe (Child-Pugh A to C): 200 mg PO qDay

Hepatotoxicity

  • Liver transaminases >5X ULN: Hold dosing until recovery to ≤2.5X ULN; resume at 400 mg qDay thereafter; discontinue if recovery takes longer than 4 weeks
  • Liver transaminase elevations ≥3X ULN concurrently with bilirubin elevations >2X ULN and alkaline phosphatase <2X ULN (Hy’s law case definition): Discontinue treatment

Diarrhea

  • Grade 3-4 diarrhea (≥7 stools/day over baseline/pretreatment): Hold dosing until recovery to Grade ≤1; may resume dose at 400 mg qDay

Other moderate or severe nonhematologic toxicities

  • Withhold dose until toxicity resolved, and then consider reducing dose by 100 mg/day
  • If clinically appropriate, consider re-escalating to the starting dose taken qDay
  • Doses <300 mg/day have been used in patients; however, efficacy has not been established

Myelosuppression

  • ANC <1000 x10^6/L or platelets <50,000 x10^6/L: Withhold dose until ANC ≥1000x10^6/L and platelets ≥50,000x10^6/L
  • Resume treatment with same dose if recovery occurs within 2 weeks
  • If blood counts remain low for >2 weeks, upon recovery, reduce dose by 100 mg and resume treatment
  • If cytopenia recurs, reduce dose by an additional 100 mg upon recovery and resume treatment
  • Doses <300 mg/day have been used in patients; however, efficacy has not been established

Coadministration with CYP3A and/or P-gp inhibitors

  • Strong or moderate CYP3A and/or P-gp inhibitors: Avoid concomitant use; increase bosutinib plasma concentration expected and possible increased risk for toxicities
  • Concomitant ketoconazole (strong CYP3A inhibitor) increased bosutinib Cmax 5.2-fold and AUC 8.6-fold compared to bosutinib alone

Coadministration with CYP3A inducers

  • Strong or moderate CYP3A inducers: Avoid concomitant use; large reduction in exposure to bosutinib expected
  • Coadministration with rifampin (strong inducer) decreased bosutinib Cmax by 86% and AUC by 94% compared to bosutinib alone

Coadministration with proton pump inhibitors

  • PPI inhibitors: Avoid concomitant use
  • As an alternative to PPIs, use short acting antacids or H2 blockers and separate dosing by more than 2 hours from bosutinib dose

Dosing Considerations

Newly-diagnosed chronic phase Ph+ CML

  • Approved under accelerated approval based on molecular and cytogenetic response rates
  • Continued approval for this indication may be contingent upon verification and confirmation of clinical benefit in an ongoing long term follow up trial

<18 years: Safety and efficacy not established

Next:

Interactions

Interaction Checker

and bosutinib

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10% (Chronic Phase CML)

            Platelet count <50×10^9/L (26%)

            Neutrophil count <1×10^9/L (16%)

            Hemoglobin <80 g/L (13%)

            SGPT/ALT >5X ULN (11%)

            All grades

            • Diarrhea (85%)
            • Nausea (47%)
            • Abdominal pain (42%)
            • Rash (42%)
            • Thrombocytopenia (40%)
            • Vomiting (37%)
            • Anemia (27%)
            • Fatigue (26%)
            • Pyrexia (23%)
            • Cough (22%)
            • Headache (21%)
            • Increased ALT/AST (17-20%)
            • Edema (20%)
            • Neutropenia (18%)
            • Arthralgia (17%)

            Grade 3/4

            • Thrombocytopenia (26%)
            • Neutropenia (22%)
            • Anemia (11%)

            >10% (Advanced Phase CML)

            Platelet count <50×10^9/L (57%)

            Neutrophil count <1×10^9/L (39%)

            Hemoglobin <80 g/L (38%)

            All grades

            • Diarrhea (76%)
            • Nausea (48%)
            • Abdominal pain (31%)
            • Rash (38%)
            • Thrombocytopenia (45%)
            • Vomiting (43%)
            • Anemia (38%)
            • Pyrexia (37%)
            • Cough (22%)
            • Neutropenia (22%)
            • Fatigue (21%)
            • Dyspnea (20%)
            • Headache (17%)
            • Edema (17%)
            • Respiratory tract infection (15%)

            Grade 3/4

            • Thrombocytopenia (39%)
            • Anemia (27%)
            • Neutropenia (20%)
            • Leukopenia (12%)

            1-10% (Chronic Phase CML)

            Lipase >2X ULN (10%)

            Phosphorus <0.6 mmol/L (7%)

            SGOT/AST >5X ULN (5%)

            Total bilirubin >3X ULN (1%)

            1-10%

            • Febrile neutropenia
            • Pericardial effusion
            • Tinnitus
            • Gastritis
            • Chest pain
            • Pain
            • Hepatotoxicity
            • Abnormal hepatic function
            • Drug hypersensitivity
            • Pneumoniae, influenza, bronchitis, pleural effusion
            • Electrocardiogram QT prolonged
            • Increased blood CPK
            • Increased blood creatinine, renal failure
            • Hyperkalemia
            • Dehydration

            All grades

            • Leukopenia (10%)
            • Increased serum creatinine (10%)
            • Influenza (10%) Chest pain (7%)

            Grade 3/4

            • Diarrhea (9%)
            • Rash (9%)
            • Increased ALT (8%)
            • Leukopenia (4%)
            • Vomiting (3%)
            • Increased AST (3%)
            • Fatigue (2%)
            • Abdominal pain (2%)
            • Asthenia (2%)
            • Dyspnea (2%)
            • Nausea (1%)
            • Edema (1%)

            1-10% (Advanced Phase CML)

            SGPT/ALT >5X ULN (9%)

            Lipase >2X ULN (9%)

            Low Phosphorus <0.6 mmol/L (7%)

            SGOT/AST >5X ULN (4%)

            Total bilirubin >3X ULN (1%)

            All grades

            • Increased ALT (10%)
            • Respiratory tract infection (10%)
            • Pleural effusion (9%)
            • Back pain (8%)
            • Pruritus (7%)
            • Nasopharyngitis (6%)
            • Increased serum creatinine (6%)
            • Influenza (3%)

            Grade 3/4

            • Abdominal pain (6%)
            • Dyspnea (6%)
            • Rash (5%)
            • Increased ALT (5%)
            • Diarrhea (4%)
            • Pleural effusion (4%)
            • Increased AST (3%)
            • Vomiting (3%)
            • Edema (2%)
            • Nausea (2%)
            • Back pain (1%)
            • Influenza (1%)

            <1% (Chronic Phase CML)

            <1%

            • Pericarditis
            • Acute pancreatitis
            • GI hemorrhage
            • Liver injury
            • Anaphylactic shock
            • Acute pulmonary edema
            • Respiratory failure
            • Pulmonary hypertension
            • Erythema multiforme
            • Exfoliative rash
            • Drug eruption

            All grades

            • Influenza
            • Increased serum creatinine
            • Pruritus
            • Respiratory tract infection
            • Decreased appetite
            • Back pain
            • Arthralgia
            • Headache
            • Pyrexia

            <1% (Advanced Phase CML)

            Asthenia

            Dizziness

            Increased serum creatinine

            Postmarketing Reports

            Hypertension

            Steven's Johnson Syndrome

            Thrombotic microangiopathy

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Cautions

            See Dosage Modifications regarding withholding, decreasing, or discontinuing bosutinib treatment with various toxicities

            Diarrhea, nausea, vomiting, and abdominal pain may occur

            Thrombocytopenia, anemia, and neutropenia occur with treatment; perform CBC weekly for first month and then monthly thereafter, or as clinically indicated

            Fluid retention may occur and manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema

            Decline in glomerular filtration rate reported in patients receiving therapy, which in turn increases bosutinib exposure in patients; use caution in patients with moderate renal impairment; dosage adjustment recommended

            Fetal harm may occur when bosutinib is administered to a pregnant woman (see Pregnancy)

            Hepatic toxicity

            • Elevated ALT, AST, and/or bilirubin may occur; perform monthly hepatic enzyme tests for first 3 months during treatment, and then as clinically indicated
            • Median time to onset of increased ALT and AST was 35 and 33 days; median duration for each was 21 days
            • Perform hepatic enzyme tests monthly for the first 3 months of treatment and as clinically indicated; in patients with transaminase elevations, monitor liver enzymes more frequently

            Drug interactions overview

            • See Dosage Modifications
            • Drugs that may increase bosutinib plasma levels: CYP3A or P-glycoprotein (P-gp) inhibitors
            • Drugs that may decrease bosutinib plasma concentrations: CYP3A inducers, proton pump inhibitors
            • Bosutinib altering plasma concentrations of drugs: Increases P-gp substrates
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            No data are available in pregnant women to inform the drug-associated risk, however, fetal harm may occur when administered to pregnant women based on mechanism of action and findings from animal studies

            Advise pregnant women of the potential risk to a fetus Females of reproductive potential should have a pregnancy test prior to initiating treatment with bosutinib

            Advise females of reproductive potential to use effective contraception (methods that result in less than 1% pregnancy rates) during treatment and for at least 1 month after the last dose

            Risk of infertility in females or males of reproductive potential has not been studied in humans; reduced fertility in females and males of reproductive potential may occur based on animal studies

            Animal data

            • In animal reproduction studies conducted in rats and rabbits, oral administration of bosutinib caused adverse developmental outcomes
            • Bosutinib administration to rats prior to fertilization until gestation day (GD) 7 caused increased embryonic resorptions at maternal exposures (AUC) ~0.5 and 0.4 times the human exposure at recommended doses of 400 and 500 mg/day, respectively, and decreased implantations and reduced number of viable embryos at maternal exposures ~1.8 and 1.3 times the human exposure at recommended doses of 400 or 500 mg/day, respectively
            • Administration of bosutinib to pregnant rabbits during organogenesis caused adverse developmental outcomes including fetal anomalies and reduced fetal body weights at maternal exposures (AUC) ~2.3 and 1.7 times the human exposure at the recommended doses of 400 or 500 mg/day

            Lactation

            Unknown whether distributed in breast milk; a decision should be made whether to discontinue nursing or to discontinue the drug

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Tyrosine kinase inhibitor; Inhibits Bcr-Abl kinase that promotes CML; also inhibits SRc-family kinases including Src, Lyn, and Hck

            Bosutinib inhibited 16 of 18 imatinib-resistant forms of Bcr-Abl expressed in murine myeloid cell lines, but did not inhibit T315I and V299L mutant cells

            Absorption

            Absolute bioavailability: 34% (healthy volunteers with food)

            Peak plasma time, 500 mg dose with food: 6 hr

            Mean peak plasma concentration, doses 200-800 mg: 146 ng/mL; increased 1.8-fold with high fat meal

            Mean AUC, doses 200-800 mg: 2720 ng•h/mL; increased 1.7-fold with high fat meal

            Distribution

            Protein Bound: 94(in vivo); 96% (ex vivo)

            Vd: 6,080 L

            P-gp substrate and inhibitor

            Metabolism

            Metabolized by in liver primarily by CYP3A4

            Metabolites (inactive): Oxydechlorinated (M2) bosutinib (19% of parent exposure) and N-desmethylated (M5) bosutinib (25% of parent exposure), with bosutinib N-oxide (M6) as a minor circulating metabolite

            Elimination

            Half-life: 22.5 hr (single oral dose); 35.5 hr (single 120-mg IV dose)

            Clearance: 63.6 L/hr

            Excretion: Feces (91.3%); urine (3%

            Previous
            Next:

            Administration

            Oral Administration

            Take with food

            Swallow table whole; do not chew, crush, or cut

            Missed dose

            • Missed dose >12 hr: Skip dose and take the usual prescribed dose on the following day

            Storage

            Tablets: Store at 68-77°F (20-25°C)

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.